- Home
- ONCY vs HLVX Comparison
ONCY vs HLVX Comparison
Compare ONCY & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- HLVX
- Stock Information
- Founded
- ONCY 1998
- HLVX 2020
- Country
- ONCY Canada
- HLVX United States
- Employees
- ONCY N/A
- HLVX N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- HLVX Health Care
- Exchange
- ONCY Nasdaq
- HLVX Nasdaq
- Market Cap
- ONCY 89.7M
- HLVX 104.3M
- IPO Year
- ONCY 1999
- HLVX 2022
- Fundamental
- Price
- ONCY $1.36
- HLVX $2.09
- Analyst Decision
- ONCY Strong Buy
- HLVX Hold
- Analyst Count
- ONCY 5
- HLVX 1
- Target Price
- ONCY $5.00
- HLVX $2.00
- AVG Volume (30 Days)
- ONCY 1.3M
- HLVX 862.9K
- Earning Date
- ONCY 11-11-2025
- HLVX 11-06-2025
- Dividend Yield
- ONCY N/A
- HLVX N/A
- EPS Growth
- ONCY N/A
- HLVX N/A
- EPS
- ONCY N/A
- HLVX N/A
- Revenue
- ONCY N/A
- HLVX N/A
- Revenue This Year
- ONCY N/A
- HLVX N/A
- Revenue Next Year
- ONCY N/A
- HLVX N/A
- P/E Ratio
- ONCY N/A
- HLVX N/A
- Revenue Growth
- ONCY N/A
- HLVX N/A
- 52 Week Low
- ONCY $0.33
- HLVX $1.34
- 52 Week High
- ONCY $1.53
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- ONCY 64.50
- HLVX 51.29
- Support Level
- ONCY $1.20
- HLVX $2.07
- Resistance Level
- ONCY $1.44
- HLVX $2.11
- Average True Range (ATR)
- ONCY 0.11
- HLVX 0.02
- MACD
- ONCY 0.01
- HLVX -0.00
- Stochastic Oscillator
- ONCY 81.40
- HLVX 50.00
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.